Clinical Trial Update: Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine [Phase 2]

View source ↗

Summary

A Phase 2 long-term study of Clairleaf (BI 1291583) in bronchiectasis is ongoing, enrolling participants who previously took part in a prior BI 1291583 study; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiectasis

Drugs mentioned

• Clairleaf (BI 1291583)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Bronchiectasis | Phase 2 | Status: ACTIVE_NOT_RECRUITING